Early‑phase research is defined by uncertainty. The safety profile is still emerging, the protocol is being tested for the first time, and the smallest decision can influence the entire trajectory of a programme.
In this blog, Mariya Kalinova, Medical Director, together with Rachna Goburdhun and Rashmi Bhadange, Study Physicians within hVIVO’s medical monitoring team, set out why medical monitoring should not be viewed as a back‑end safety function, but as a stabilising force that underpins study coherence, ethical integrity, and scientific rigour from the moment a protocol is conceived.
At hVIVO, our medical monitoring team was built with this philosophy in mind. We are physicians with backgrounds in internal medicine, anaesthetics, intensive care, infectious disease, and respiratory medicine. Many of us have served as principal investigators ourselves. We understand what it means to run a study, to care for participants, and to make decisions when the protocol meets real patients.
Our role is simple to describe but complex to execute: we help sponsors design safer, clearer, more resilient studies — and we help investigators navigate them with confidence.
The most preventable problems in early‑phase research happen before the first participant is ever screened. Eligibility criteria that are too vague. Safety rules that are too rigid or too loose. Dosing schedules that don’t reflect real‑world physiology. Risk‑benefit thresholds that are unclear. Protocols that don’t anticipate the scenarios investigators will inevitably face.
When medical monitors are involved early, these issues are addressed before they become obstacles. We review the protocol, the safety management plan, the regulatory submission package, and the operational flow. We look for the gaps that only become visible when you’ve run dozens of studies and managed hundreds of participants.
Early involvement is not a luxury. It is the difference between a study that runs smoothly and one that spends its time reacting to avoidable problems.
Every decision in a clinical trial sits at the intersection of three forces: patient safety, scientific validity, and regulatory defensibility. Most roles in a study lean toward one of these. Medical monitors must hold all three at once.
We assess adverse events not only for what they mean clinically, but for what they mean scientifically and how they will be interpreted months later by regulators. We guide investigators through borderline eligibility decisions, dosing questions, and unexpected lab results. We help determine whether a participant can safely continue, whether additional assessments are needed, and how to document decisions in a way that protects both the patient and the study.
This is not about enforcing rules. It is about applying judgment — the kind that comes from experience, pattern recognition, and a deep understanding of how early‑phase research behaves in the real world.
Protocols are written in controlled language. Patients are not. They arrive with comorbidities, medications, borderline lab values, unexpected symptoms, and life events that don’t fit neatly into a flowchart.
This is where medical monitors become indispensable.
We help investigators interpret what they’re seeing. We talk through scenarios that aren’t explicitly covered in the protocol. We advise on how to manage challenging cases, when to escalate, when to pause, and when to continue. We help determine whether a finding is clinically meaningful or simply noise. We support decisions that protect participants without compromising the scientific integrity of the study.
The best investigators know that medical monitors are not there to override them — we are there to support them. To be the colleague they can call when something doesn’t look quite right. To help them make decisions that are safe, defensible, and aligned with the intent of the study.
Medical monitors do not have more data than the site. We have the same data — but we bring a broader lens.
We see patterns across participants, not just within one. We recognize when a lab abnormality is a known effect of a respiratory pathogen rather than a sign of toxicity. We notice when a cluster of symptoms suggests a dosing issue, a formulation issue, or a protocol mismatch. We identify when an unexpected finding may influence the future development of the product.
This interpretive role is especially important in early‑phase respiratory studies, where symptoms, immune responses, and viral dynamics can overlap in ways that are easy to misread. Our experience with controlled human infection models — including the world’s first COVID‑19 challenge study — gives us a unique understanding of how respiratory pathogens behave and how to distinguish expected effects from true safety concerns.
Safety and science are only part of the equation. Early‑phase research often involves vulnerable populations, sensitive scenarios, and decisions that carry ethical weight. Pregnancy reporting, unexpected comorbidities, emergency care, and borderline risk‑benefit situations all require careful judgment.
Medical monitors help investigators navigate these moments with clarity and compassion. We ensure that decisions are ethically sound, appropriately documented, and aligned with both regulatory expectations and the well‑being of the participant.
Ethics is not a separate layer of oversight. It is woven into every decision we make.
Early‑phase research works best when every function is connected: protocol design, clinical operations, laboratory science, challenge models, and data interpretation. Medical monitoring strengthens this ecosystem by ensuring that the study remains coherent as it unfolds. We stabilize the protocol when real‑world complexity appears. We help investigators make decisions that protect both participants and data. We prevent small uncertainties from becoming large deviations.
And we ensure that the evidence generated is clear, defensible, and meaningful for the next phase of development.
In a landscape where early‑phase studies are becoming more complex, more global, and more time‑sensitive, this role is not optional. It is foundational.
Medical monitoring is often described as a safety function. In reality, it is a design function, a judgment function, and a coherence function. It is the discipline that keeps early‑phase research aligned with reality — and aligned with its purpose.
When medical monitors are involved early, studies run more smoothly. When they are trusted partners to investigators, participants are safer. When they apply their clinical judgment to ambiguous situations, the science becomes clearer. And when they help sponsors navigate uncertainty, the entire programme becomes more resilient.
Early‑phase research will always involve unknowns. Medical monitoring ensures those unknowns are managed with expertise, clarity, and care.